About LYFCX
AlphaCentric Life Sciences and Healthcare Fund Class C is a mutual fund that aims for long-term capital appreciation by investing primarily in companies within the life sciences and healthcare industries. The fund allocates at least 80% of its net assets, including borrowings, to equity securities of firms involved in pharmaceuticals, biotechnology, medical technology, healthcare equipment, and related services. Its portfolio includes a mix of large, medium, and small capitalization companies, with notable holdings in industry leaders such as Eli Lilly, UnitedHealth Group, and Johnson & Johnson. The fund holds approximately 64 positions, with nearly half of its assets concentrated in its top ten holdings, reflecting a focused approach to sector selection. It serves investors seeking exposure to advancements in healthcare and biotechnology, tapping into trends in medical innovation, healthcare provision, and global health solutions. With a semi-annual dividend payout and an inception date of November 2019, this fund plays a specialized role in the market, targeting growth through the evolving landscape of health and life sciences sectors.
Fund Family AlphaCentric Funds
Category Health
Performance Rating Average
Risk Rating Above Average
Stock Exchange Nasdaq
Ticker Symbol LYFCX
Share Class Class C
Index S&P 500 TR
LYFCX had a total return of 21.50% in the past year, including dividends. Since the fund's
inception, the average annual return has been 11.48%.
